Bellicum Pharmaceuticals, Inc.
AcquiredHouston, US · 5 known investors
Find your way into Bellicum Pharmaceuticals, Inc.
Sign up to see every warm intro you have to Bellicum Pharmaceuticals, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bellicum Pharmaceuticals, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by The University of Texas MD Anderson Cancer Center February 2024 · $8.1M ($8.1 million in cash for substantially all assets) · source ↗
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
Founders & leadership
Board
Investors · 5
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$114.2M disclosed across 2 rounds · 2011–2014
▶$94.4MraisedSep 2014 · 76 investors · PharmaceuticalsRule 506(b)
- David M. SpencerExecutive Officer
- Annemarie MoseleyExecutive Officer
- Kevin M. SlawinDirector
- Dennis K. StoneDirector
- James F. BrownDirector
- Frank McGuyerDirector
- Ken MoseleyExecutive Officer
- Thomas J. FarrellExecutive Officer, Director
- Offering amount
- $94.4M
- Amount sold
- $94.4M
- Sales commissions
- $3.1M
- Placement agents
- Jefferies LLC
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.9MraisedMar 2012 · 21 investors · PharmaceuticalsRule 506(b)
- Ken MoseleyExecutive Officer
- Thomas J. FarrellExecutive Officer, Director
- James F. BrownDirector
- Annemarie MoseleyExecutive Officer
- Joseph SenesacExecutive Officer
- Frank McGuyerDirector
- David M. SpencerExecutive Officer
- Dennis K. StoneDirector
- Kevin M. SlawinExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $19.9M
- Minimum investment
- $1M
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Bellicum Pharmaceuticals, Inc. went on to found or lead other companies.
Frequently asked questions
- What does Bellicum Pharmaceuticals, Inc. do?
- Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
- Who founded Bellicum Pharmaceuticals, Inc.?
- Bellicum Pharmaceuticals, Inc. was founded by David M. Spencer.
- Who are Bellicum Pharmaceuticals, Inc.'s investors?
- Bellicum Pharmaceuticals, Inc.'s investors include Avoro Capital Advisors, Foresite Capital, RA Capital, Rapha Capital Management, LLC, Solasta Ventures.
- How much funding has Bellicum Pharmaceuticals, Inc. raised?
- Bellicum Pharmaceuticals, Inc. has disclosed $114.2M raised across 2 rounds.
- Where is Bellicum Pharmaceuticals, Inc. headquartered?
- Bellicum Pharmaceuticals, Inc. is headquartered in Houston, US.






